Cell-based immunotherapy

Immunotherapy is utilizing a patient’s own immune system to fight cancer as well as other diseases. Our immune system is capable of recognizing and eliminating cells that have become infected or damaged or become cancerous. Whereas radiation therapy or chemical therapy target the tumor itself, cancer immunotherapy focuses on boosting the activity of the immune system to erase the tumor. The strategies make use of the fact that many cancer cells express cancer antigens which can be detected by the immune system.

Request info

The natural immune response may not be effective against tumors because a tumor may exploit several mechanisms to evade detection by the immune system: For example, the tumor may not express specific antigens or it has major histocompatibility complex (MHC) mutations, so that the immune system does not recognize the tumor. Or, the tumor may produce immune-suppressive molecules that inactivate the immune cells. Thus, boosting the immune response is used to overcome such evasive mechanisms.

In the early days, cancer immunotherapy mainly focused on immuno-stimulatory cytokine treatments. Cytokines, the intercellular signaling molecules of the immune system, can either exert a direct antitumor effect (e.g. TNF-α or Il-6) or indirectly enhance the antitumor immune response (e.g. IL-2 or IFN-α).

Need specific characteristics or donors?

With CellFindR^®, we’re here to help!

Our new guided interface easily helps you search based on key donor characteristics to find the perfect match.

Explore now

New cell-based immunotherapy approaches

More recent strategies focus on the increase of tumor-specific T cells, the most common treatments are antibody therapy, immune checkpoint inhibitors, cancer vaccines and cell-based immunotherapy.

Cell-based immunotherapy leverages immune cell types that are able to fight cancer due to their ability to bind to recognize and activate to kill cancer cells. Treatment regimens use a cell type from the immune system as therapeutic agent. For this purpose, the cells are first removed from the body, then activated or modified, expanded and finally re-infused into the patient.

Cell-based immunotherapies involve, but are not limited to, the following approaches:

Tumor-infiltrating lymphocyte (TIL) therapy

TIL therapy is a form of  adoptive cell therapy that harvests naturally occurring T cells that have already infiltrated patients’ tumors. These cells are then activated and expanded. Activated T cells are re-infused into patients, where they can then seek out and destroy tumors.

Engineered T-cell receptor therapy

Another type of adoptive therapy involves use of peripheral blood T cells genetically engineered ex vivo which express a cancer-specific T cell receptor (TCR). This approach involves taking T cells from patients, and an additional step of transfecting the cells with a new T cell receptor is performed. This enables them to target specific cancer antigens.